Janssen Of Japan To Develop ER Painkiller Patch Solely For Japan
This article was originally published in PharmAsia News
Japan's Janssen Pharmaceutical, a subsidiary of U.S.-based Johnson & Johnson, has applied to develop an extended-release painkiller developed for the Japanese market. Janssen's Durotep (fentanyl) is a one-day analgesic patch, which the firm hopes to be able to begin marketing next year. The patch is available as a three-day treatment, but patients complained they needed to change the patch so they could bathe daily. Janssen used the technology of a J&J joint venture with biotech Alza to develop an extended-release version. (Click here for more - a subscription may be required
You may also be interested in...
ODAC's 17-18 June discussion of pediatric development plans for four investigational oncology agents will serve as a trial run of the technology platform and logistics for any future application-specific virtual advisory committee meeting, but without the stress associated with a pending application and a user fee deadline.
Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.
Ambitious efforts to make the EU more resilient to future challenges, such as health threats, drug supply problems, scientific advances and growing medicine costs, have taken a step forward with the publication of a roadmap for a wide-ranging Pharmaceutical Strategy to be adopted by the European Commission later in the year.